Anterior Gen Plus Study

NCT ID: NCT04629807

Last Updated: 2023-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-15

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study evaluating patients treated with the Demineralized Bone Matrix (DBM) as compared to a Cellular Bone Matrix (CBM) in anterior lumbar interbody fusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective, single-center, clinical study evaluating patients undergoing primary, contiguous 2-level ALIF without supplemental fixation treated with Demineralized Bone Matrix (DBM) as compared to a Cellular Bone Matrix (CBM).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spine Fusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Demineralized Bone Matrix (DBM)

All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Study Implant (one-level) implanted with Demineralized Bone Matrix (DBM).

Group Type ACTIVE_COMPARATOR

Anterior Lumbar Interbody Fusion (ALIF)

Intervention Type PROCEDURE

Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)

Cellular Bone Matrix (CBM)

All enrolled subjects will undergo primary, contiguous 2-level ALIF without supplemental fixation. Control Implant (one-level) implanted with Cellular Bone Matrix (CBM).

Group Type ACTIVE_COMPARATOR

Anterior Lumbar Interbody Fusion (ALIF)

Intervention Type PROCEDURE

Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anterior Lumbar Interbody Fusion (ALIF)

Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years of age
* Requires anterior lumbar interbody (ALIF) fusion
* Are physically and mentally able and willing to return for the scheduled follow up visits, follow post-operative instructions
* Willing and able to sign study specific Informed Consent Form

Exclusion Criteria

* Signs of acute infection
* Active malignancy and/or current chemotherapy
* Prior fusion at operative or adjacent level
* Institutionalized or a prisoner
* Documented history of alcohol or drug abuse
* Undergoing a worker's compensation case
* Pregnancy
* Participation in another research study involving another implant or drug that may affect the outcomes of this clinical study
* Any other condition that the Investigator determines is unacceptable for enrollment into this clinical study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SeaSpine, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muwaffak Abdulhak, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Health System

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Henry Ford Health System

Detroit, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SS-OS-1901

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Allogeinic Bone Paste
NCT04605120 UNKNOWN NA
Sterile Amniotic Fluid Filtrate Epidural Injection.
NCT04537026 COMPLETED PHASE1/PHASE2